359 523

Cited 59 times in

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

DC Field Value Language
dc.contributor.author이정윤-
dc.contributor.author김현수-
dc.date.accessioned2020-02-11T06:11:42Z-
dc.date.available2020-02-11T06:11:42Z-
dc.date.issued2019-
dc.identifier.issn0090-8258-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/174579-
dc.description.abstractOBJECTIVE: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. METHODS: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3-4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). RESULTS: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5-65) and 28 months (IQR 7-92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45-0·66; P < 0·001) and 0·65 (95% CI 0·50-0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). CONCLUSIONS: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherAcademic Press-
dc.relation.isPartOfGYNECOLOGIC ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorPaul A.Cohen-
dc.contributor.googleauthorAimePowell-
dc.contributor.googleauthorSteffenBöhm-
dc.contributor.googleauthorC.BlakeGilks-
dc.contributor.googleauthorColinJ.R.Stewart-
dc.contributor.googleauthorTarekM.Meniawy-
dc.contributor.googleauthorMaxBulsara-
dc.contributor.googleauthorStefanieAvril-
dc.contributor.googleauthorEleanorC.Brockbank-
dc.contributor.googleauthorTjallingBosse-
dc.contributor.googleauthorGustavo RubinodeAzevedoFocchi-
dc.contributor.googleauthorRajiGanesan-
dc.contributor.googleauthorRosalindM.Glasspool-
dc.contributor.googleauthorBrookeE.Howitt-
dc.contributor.googleauthorHyun-Soo Kim-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorNhuD.Le-
dc.contributor.googleauthorMichelleLockley-
dc.contributor.googleauthorRanjitManchanda-
dc.contributor.googleauthorTruptiMandalia-
dc.contributor.googleauthorW.GlennMcCluggage-
dc.contributor.googleauthorIainMcNeish-
dc.contributor.googleauthorDivyaMidha-
dc.contributor.googleauthorRadhikaSrinivasan-
dc.contributor.googleauthorYunYiTan-
dc.contributor.googleauthorRachaelvanderGriend-
dc.contributor.googleauthorMayuYunokawa-
dc.contributor.googleauthorGianF.Zannoni-
dc.contributor.googleauthorThe HGSCCRS Collaborative Network Takahiro Ebata af-
dc.contributor.googleauthorNaveenaSingh ag-
dc.contributor.googleauthorKenjiTamura ag-
dc.contributor.googleauthorHiroshiYoshida-
dc.identifier.doi10.1016/j.ygyno.2019.04.679-
dc.contributor.localIdA04638-
dc.relation.journalcodeJ00956-
dc.identifier.eissn1095-6859-
dc.identifier.pmid31118141-
dc.subject.keywordChemotherapy response score-
dc.subject.keywordHigh-grade serous tubo-ovarian cancer-
dc.subject.keywordNeoadjuvant chemotherapy-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameLee, Jung-Yun-
dc.contributor.affiliatedAuthor이정윤-
dc.citation.volume154-
dc.citation.number2-
dc.citation.startPage441-
dc.citation.endPage448-
dc.identifier.bibliographicCitationGYNECOLOGIC ONCOLOGY, Vol.154(2) : 441-448, 2019-
dc.identifier.rimsid63972-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.